Efficacy of lamivudine and thymosin alpha-1 combination therapy in treatment of HBeAg-positive chronic hepatitis B: a meta-analysis

Efficacy of lamivudine and thymosin alpha-1 combination therapy in treatment of HBeAg-positive chronic hepatitis B: a meta-analysis

ObjectiveTo evaluate the efficacy of lamivudine and thymosin alpha-1 combination therapy in the treatment of HBeAg-positive chronic hepatitis B (CHB) by meta-analysis. MethodsRandomized controlled trials (RCTs) of lamivudine and thymosin alpha-1 combination therapy in treatment of HBeAg-positive CHB...

Full description

Bibliographic Details
Main Author:	QI Youtao
Format:	Article
Language:	zho
Published:	Editorial Department of Journal of Clinical Hepatology 2014-07-01
Series:	Linchuang Gandanbing Zazhi
Subjects:	hepatitis B chronic; lamivudine; thymosin; Meta-analysis
Online Access:	http://www.lcgdbzz.org/qk_content.asp?id=5962&ClassID=71494937

Similar Items

The effects of prolonged Lamivudine administration as a sole treatment following the combination therapy of Interferon Alpha and Lamivudine in children for HBeAg (+) chronic hepatitis B
by: Sezin Asik Akman,1 Sabriye Cokceken Okcu,2 Sumer Sutcuoglu.2
Published: (2007-10-01)

Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B
by: HUANG Meijin
Published: (2014-07-01)

Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B
by: MA Yanhong
Published: (2013-08-01)

Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B: preliminary comparative study
by: YAN Haiming
Published: (2013-07-01)

Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma
by: Adriano M. Pellicelli, M.D., et al.
Published: (2014-07-01)

Lamivudine for chronic hepatitis B: a brief review
by: Emilio Palumbo

Lamivudine therapy for chronic hepatitis B in children: a meta-analysis
by: Aoran Luo, et al.
Published: (2019-07-01)

Lamivudine therapy for hepatitis B in renal transplantation
by: F.R.L. Santos, et al.
Published: (2002-02-01)

HBeAg-negative chronic hepatitis
by: M M Ibragimova, et al.
Published: (2004-02-01)

Treatment of chronic hepatitis B in Oman experience with lamivudine
by: Upadhyay Dip Amal, et al.
Published: (2003-01-01)

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
by: Chan Ho Park, et al.
Published: (2016-03-01)

Predictive value of HBcrAg for lamivudine resistance in patients with chronic hepatitis B
by: LIU Cheng
Published: (2013-11-01)

Experience with lamivudine treatment for severe acute hepatitis B
by: Verhaz Antonija
Published: (2014-01-01)

Significance of changes in hepatic histology from patients with HBeAg(+) or HBeAg(-) chronic hepatitis B and normal or mildly elevated alanine aminotransferase
by: LAN Lin
Published: (2015-04-01)

The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis
by: Dan Peng, et al.
Published: (2020-10-01)

THYMUS PEPTIDES (THYMULIN, THYMOSIN ALPHA 1 AND THYMOSIN BETA 4) INHIBITING EFFECTS ON THE INTRINSIC BLOOD COAGULATION PATHWAY IN RATS
by: Negrin Negrev, et al.
Published: (2017-08-01)

Efficacy and safety on tenofovire therapy in patients with hepatitis B viral infections resistent to lamivudin
by: Katanić N., et al.
Published: (2015-01-01)

Acute pancreatitis associated with lamivudine therapy for chronic B hepatitis
by: Felipe Francisco Tuon, et al.

Mutation Pattern of Lamivudine Resistance in Relation to Hepatitis B Genotypes
by: Damerow, Hans
Published: (2012)

Efficacy of low-dose interferon α-1b combined with ribavirin and thymosin α1 versus standard treatment for chronic hepatitis C: a comparative study
by: SUN Jianmin
Published: (2015-01-01)

Lamivudine therapy in HBeAg negative chronic hepatitis B patients
by: E. Guclu, et al.
Published: (2014-04-01)

HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review
by: Yun Zhang, et al.

Langzeiteffektivität der Therapie mit Lamivudin bei Patienten mit chronischer Hepatitis-B-Virus-Infektion – Prädiktion des Langzeitansprechens und Spektrum der Resistenzentwicklung
by: Brodzinski, Annika
Published: (2015)

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
by: Joo An Hwang, et al.
Published: (2015-06-01)

Immunoreactivity for thymosin beta 4 and thymosin beta 10 in the adult rat oro-gastro-intestinal tract
by: S. Nemolato, et al.
Published: (2013-05-01)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
by: Jeong Han Kim, et al.
Published: (2013-09-01)

Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B
by: Astrid Wiens, et al.

Effects of Thymosin Alpha-1 on Radiation-induced Pneumonitis
by: Rong YU, et al.
Published: (2011-03-01)

Potential Role of Thymosin Beta 4 in Liver Fibrosis
by: Jieun Kim, et al.
Published: (2015-05-01)

The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: A meta-analysis
by: Jun-Ying Liu, et al.
Published: (2015-02-01)

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
by: Jeong Han Kim, et al.
Published: (2014-09-01)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
by: Hu Peng, et al.
Published: (2011-08-01)

Rhabdomyolysis due to Lamivudine administration in acute viral hepatitis B infection: a case report from Malaysia
by: Janudin Baharin, et al.
Published: (2014-03-01)

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon α
by: Hu Yao-ren, et al.
Published: (2014-03-01)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
by: Hee-Jeong Jeon, et al.
Published: (2017-09-01)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
by: EunYoung Ze, et al.
Published: (2014-09-01)

Evaluation of the therapeutic efficacy of lamivudine combined with plasma exchange for treating acute-on-chronic hepatitis B liver failure
by: HU Qijiang
Published: (2013-02-01)

Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis
by: Congcong Li, et al.
Published: (2015-04-01)

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
by: Cheng-Yuan Peng, et al.
Published: (2015-04-01)

Depletion of Thymosin β4 Promotes the Proliferation, Migration, and Activation of Human Hepatic Stellate Cells
by: Yongtao Xiao, et al.
Published: (2014-07-01)

Cannot write session to /tmp/vufind_sessions/sess_go4s69vqd7b0m8nfmspjd9ulfu